Clinical Trials
Manhattan Hematology Oncology Associates
AML-FLT3
Now enrolling patients for a phase 2/3 clinical study for the treatment of AML patients with FLT3 mutations who are not eligible for intensive induction therapy.
The study will evaluate treatments with:
ASP2215 (Gilteritinib)
ASP2215 Plus Azacitidine
Azacitidine Alone
Gilteritinib has demonstrated inhibitory activity against FLT3 internal tandem duplication (ITD), as well as tyrosine kinase domain (TKD), two common types of FLT3 mutations that are seen in 1/3 of patients with Acute Myeloid Leukemia.
MHOA Principle Investigator
Alec Goldenberg, M.D.
For additional information:
Please contact our Clinical Research Coordinator
212-689-6791 ext 228 Priscila Perez
clinicaltrials@mhony.com
Leukemia and Lymphomas MCL
Mantle cell lymphoma (MCL) Oncternal Study
Now enrolling patients for a Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies.
This research study will evaluate an investigational drug, called cirmtuzumab, in combination with a standard drug, called ibrutinib (Imbruvica®), for treatment of patients with MCL.
MHOA Principle Investigator
Alec Goldenberg, M.D.
For additional information:
Please contact our Clinical Research Coordinator
212-689-6791 ext 228 Priscila Perez
clinicaltrials@mhony.com
Myelofibrosis Abbvie Study
Now Enrolling Patients for a Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis.
MHOA Principle Investigator
Alec Goldenberg, M.D.
For additional information:
Please contact our Clinical Research Coordinator
212-689-6791 ext 228 Priscila Perez
clinicaltrials@mhony.com
Meet Our Doctors
Alec Goldenberg, M.D.
Dr. Goldenberg, Founding Physician of Manhattan Hematology Oncology Associates (MHOA), graduated Magna Cum Laude from Brandeis University with High Honors in Mathematics, before receiving his MD from The Johns Hopkins University School of Medicine in 1980. He completed his internship and residency at Bellevue-New York University Hospitals, where he was also Chief Resident. Dr. Goldenberg continued his training as a fellow at Memorial Sloan Kettering in New York City before becoming the Director of the Hematology Clinic at the NYU Medical Center. Board certified in Internal Medicine and Medical Oncology, Dr. Goldenberg is currently a Clinical Associate Professor of Medicine at the New York University School of Medicine, and an Attending Physician at New York University Medical Center.
Karen Haglof, M.D.
Dr. Karen Haglof, Associate Physician at Manhattan Hematology Oncology Associates (MHOA), graduated Summa Cum Laude from City University of New York, Hunter College before receiving her MD with Magna Cum Laude distinction from State University of New York. Completing her internship and residency in Internal Medicine at the University of Florida in Gainesville, Florida, Dr. Haglof continued her post-graduate medical training as a Hematology/Oncology Fellow at New York University in New York City. Dr. Haglof continued her strong relationship with NYU and Bellevue Hospitals, where she is currently an Attending Physician and Clinical Instructor in Hematology and Oncology.
